Tumor necrosis factor-α inhibition improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women

Atherosclerosis

Volumn 230, Issue 2, 2013, Pages 390-396

  Moreau, Kerrie L ^a   Deane, Kevin D ^a   Meditz, Amie L ^a   Kohrt, Wendy M ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Aging; Cardiovascular disease; Endothelium; Imaging; Inflammation; Menopause

Indexed keywords

C REACTIVE PROTEIN; ESTRADIOL; ETANERCEPT; INSULIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTERIAL STIFFNESS; ARTERY COMPLIANCE; ARTICLE; BRACHIAL ARTERY; CAROTID ARTERY; CLINICAL ARTICLE; DRUG ERUPTION; DRUG TOLERABILITY; FEMALE; HEADACHE; HEART RATE; HUMAN; INJECTION SITE SWELLING; INSULIN BLOOD LEVEL; OXIDATIVE STRESS; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PULSE PRESSURE; RISK FACTOR; SHEAR RATE; SYSTOLIC BLOOD PRESSURE;

AGING; CARDIOVASCULAR DISEASE; ENDOTHELIUM; IMAGING; INFLAMMATION; MENOPAUSE;

ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; BODY COMPOSITION; BRACHIAL ARTERY; CAROTID ARTERIES; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGENS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; IMMUNOGLOBULIN G; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR STIFFNESS; VASODILATION; YOUNG ADULT;

EID: 84884505021     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2013.07.057     Document Type: Article

References (26)

1. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a "set up" for vascular disease. Circulation 2003, 107:139-146.
2. Moreau K.L., Hildreth K.L., Meditz A.L., et al. Endothelial function is impaired across the stages of the menopause transition in healthy women. JClin Endocrinol Metab 2012, 97:4692-4700.
3. Nagai Y., Earley C.J., Kemper M.K., et al. Influence of age and postmenopausal estrogen replacement therapy on carotid arterial stiffness in women. Cardiovasc Res 1999, 41:307-311.
4. Moreau K.L., Gavin K.M., Plum A.E., et al. Ascorbic acid selectively improves large elastic artery compliance in postmenopausal women. Hypertension 2005, 45:1107-1112.
5. Virdis A., Ghiadoni L., Pinto S., et al. Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women. Circulation 2000, 101:2258-2263.
6. Arenas I.A., Armstrong S.J., Xu Y., et al. Chronic tumor necrosis factor-{alpha} inhibition enhances NO modulation of vascular function in estrogen-deficient rats. Hypertension 2005, 46:76-81.
7. Csiszar A., Labinskyy N., Smith K., et al. Vasculoprotective effects of anti-tumor necrosis factor-{alpha} treatment in aging. Am J Pathol 2007, 170:388-398.
8. Donato A.J., Pierce G.L., Lesniewski L.A., et al. Role of NFkappaB in age-related vascular endothelial dysfunction in humans. Aging (Albany NY) 2009, 1:678-680.
9. Novella S., Heras M., Hermenegildo C., et al. Effects of estrogen on vascular inflammation: a matter of timing. Arterioscler Thromb Vasc Biol 2012, 32:2035-2042.
10. Moreau K.L., Donato A.J., Seals D.R., et al. Regular exercise, hormone replacement therapy and the age-related decline in carotid arterial compliance in healthy women. Cardiovasc Res 2003, 57:861-868.
11. Moreau K.L., Meditz A., Deane K.D., et al. Tetrahydrobiopterin improves endothelial function and decreases arterial stiffness in estrogen-deficient postmenopausal women. Am J Physiol Heart Circ Physiol 2012, 302:H1211-H1218.
12. Corretti M.C., Anderson T.J., Benjamin E.J., et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. JAm Coll Cardiol 2002, 39:257-265.
13. Moreau K.L., Gavin K.M., Plum A.E., et al. Oxidative stress explains differences in large elastic artery compliance between sedentary and habitually exercising postmenopausal women. Menopause 2006, 13:951-958.
14. Fichtlscherer S., Rossig L., Breuer S., et al. Tumor necrosis factor antagonism with etanercept improves systemic endothelial vasoreactivity in patients with advanced heart failure. Circulation 2001, 104:3023-3025.
15. Korth-Bradley J.M., Rubin A.S., Hanna R.K., et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000, 34:161-164.
16. Bilsborough W., Keen H., Taylor A., et al. Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. Rheumatol Int 2006, 26:1125-1131.
17. Tsimberidou A.-M., Waddelow T., Kantarjian H.M., et al. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR: Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNFα levels during treatment. Leuk Res 2003, 27:375-380.
18. Madhusudan S., Foster M., Muthuramalingam S.R., et al. Aphase II study of etanercept (Enbrel), a tumor necrosis factor α inhibitor in patients with metastatic breast cancer. Clin Cancer Res 2004, 10:6528-6534.
19. Maki-Petaja K.M., Hall F.C., Booth A.D., et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor-{alpha} therapy. Circulation 2006, 114:1185-1192.
20. Blake G.J., Ridker P.M. Novel clinical markers of vascular wall inflammation. Circ Res 2001, 89:763-771.
21. Yoshizumi M., Perrella M.A., Burnett J.C., et al. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circ Res 1993, 73:205-209.
22. Madge L.A., Pober J.S. TNF signaling in vascular endothelial cells. Exp Mol Pathol 2001, 70:317-325.
23. Mittermayer F., Pleiner J., Schaller G., et al. Tetrahydrobiopterin corrects Escherichia coli endotoxin-induced endothelial dysfunction. Am J Physiol Heart Circ Physiol 2005, 289:H1752-H1757.
24. Wilkinson I.B., Qasem A., McEniery C.M., et al. Nitric oxide regulates local arterial distensibility invivo. Circulation 2002, 105:213-217.
25. Ghisletti S., Meda C., Maggi A., et al. 17beta-estradiol inhibits inflammatory gene expression by controlling NF-kappaB intracellular localization. Mol Cell Biol 2005, 25:2957-2968.
26. Majmudar N.G., Robson S.C., Ford G.A. Effects of the menopause, gender, and estrogen replacement therapy on vascular nitric oxide activity. JClin Endocrinol Metab 2000, 85:1577-1583.